Abstrakt

Przypisy

• 1. Alegre M.M., Weyant M.J., Bennett D.T., Yu J.A., Ramsden M.K.,Elnaggar A., Robison R.A., O’Neill K.L.: Serum detection of thymidinekinase 1 as a means of early detection of lung cancer. AnticancerRes., 2014; 34: 2145‑2151
  Google Scholar
• 2. Bacovsky J., Myslivecek M., Minarik J., Scudla V., Pika T., Zaple‑talova J., Petrova P., Bartkova M., Adam T., Gronowitz S.J.: Analy‑sis of thymidine kinase serum levels by novel method DiviTum inmultiple myeloma and monoclonal gammopathy of undeterminedsignificance – comparison with imaging methods 99mTc‑MIBI scin‑tigraphy and 18F‑FDG PET/CT. Biomed. Pap. Med. Fac. Univ. PalackyOlomouc Czech Repub., 2015; 159: 135‑138
  Google Scholar
• 3. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goas‑guen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tch‑ernia G., Jacquillat C., Boivin P., Lesty C., Duault M.T., MonconduitM., Belabbes S., Gremy F.: A new prognostic classification of chroniclymphocytic leukemia derived from a multivariate survival analysis.Cancer, 1981; 48: 198‑206
  Google Scholar
• 4. Di Raimondo F., Giustolisi R., Lerner S., Cacciola E., O’Brien S., Kan‑tarjian H., Keating M.J.: Retrospective study of the prognostic roleof serum thymidine kinase level in CLL patients with active diseasetreated with fludarabine. Ann. Oncol., 2001; 12: 621‑625
  Google Scholar
• 5. Gronowitz J.S., Hagberg H., Källander C.F., Simonsson B.: Theuse of serum deoxythymidine kinase as a prognostic marker, andin the monitoring of patients with non‑Hodgkin’s lymphoma. Br. J.Cancer, 1983; 47: 487‑495
  Google Scholar
• 6. Hallek M., Cheson B.D., Catovsky D., Caligaris‑Cappio F., Dighie‑ro G., Döhner H., Hillmen P., Keating M.J., Montserrat E., Rai K.R.,Kipps T.J., International Workshop on Chronic Lymphocytic Leu‑kemia: Guidelines for the diagnosis and treatment of chronic lym‑phocytic leukemia: a report from the international Workshop onChronic Lymphocytic Leukemia updating the National Cancer In‑stitute‑Working Group 1996 guidelines. Blood, 2008; 111: 5446‑5456
  Google Scholar
• 7. Hallek M., Langenmayer I., Nerl C., Knauf W., Dietzfelbinger H.,Adorf D., Ostwald M., Busch R., Kuhn‑Hallek I., Thiel E., EmmerichB.: Elevated serum thymidine kinase levels identify a subgroup athigh risk of disease progression in early, nonsmoldering chroniclymphocytic leukemia. Blood, 1999; 93: 1732‑1737
  Google Scholar
• 8. Hallek M., Wanders L., Ostwald M., Busch R., SenekowitschR., Stern S., Schick H.D., Kuhn‑Hallek I., Emmerich B.: Serumβ2‑microglobulin and serum thymidine kinase are independent pre‑dictors of progression‑free survival in chronic lymphocytic leukemiaand immunocytoma. Leuk. Lymphoma, 1996; 22: 439‑447
  Google Scholar
• 9. Hallek M., Wanders L., Strohmeyer S., Emmerich B.: Thymidinekinase: a tumor marker with prognostic value for non‑Hodgkin’slymphoma and a broad range of potential clinical applications. Ann.Hematol., 1992; 65: 1‑5
  Google Scholar
• 10. Hamblin T.: Chronic lymphocytic leukaemia: one disease or two?Ann. Hematol., 2002; 81: 299‑303
  Google Scholar
• 11. Hayat M.J., Howlader N., Reichman M.E., Edwards B.K.: Cancerstatistics, trends, and multiple primary cancer analyses from theReferencesSurveillance, Epidemiology, and End Results (SEER) Program. On‑cologist, 2007; 12: 20‑37
  Google Scholar
• 12. International CLL‑IPI working group: An international progno‑stic index for patients with chronic lymphocytic leukaemia (CLL‑IPI):a meta‑analysis of individual patient data. Lancet Oncol., 2016; 17:779‑790
  Google Scholar
• 13. Källander C.F., Simonsson B., Hagberg H., Gronowitz J.S.: Serumdeoxythymidine kinase gives prognostic information in chroniclymphocytic leukemia. Cancer, 1984; 54: 2450‑2455
  Google Scholar
• 14. Konoplev S.N., Fritsche H.A., O’Brien S., Wierda W.G., KeatingM.J., Gornet T.G., St Romain S., Wang X., Inamdar K., Johnson M.R.,Medeiros L.J., Bueso‑Ramos C.E.: High serum thymidine kinase 1 le‑vel predicts poorer survival in patients with chronic lymphocyticleukemia. Am. J. Clin. Pathol., 2010; 134: 472‑477
  Google Scholar
• 15. Kotkowska A., Wawrzyniak E., Blonski J.Z., Robak T., Koryc‑ka‑Wolowiec A.: Chromosomal aberrations in chronic lymphocy‑tic leukemia detected by conventional cytogenetics with DSP30 asa single agent: comparison with FISH. Leuk. Res., 2011; 35: 1032‑1038
  Google Scholar
• 16. Lejcko J., Jungerova J., Topolcan O., Koza V.: Thymidine kinase atmalignant lymphogranuloma and Non‑Hodgkin Lymphoma. Prakt.Lek., 1992; 72: 171‑173
  Google Scholar
• 17. Letestu R., Lévy V., Eclache V., Baran‑Marszak F., Vaur D., Na‑guib D., Schischmanoff O., Katsahian S., Nguyen‑Khac F., Davi F.,Merle‑Béral H., Troussard X., Ajchenbaum‑Cymbalista F.: Prognosisof Binet stage A chronic lymphocytic leukemia patients: the strengthof routine parameters. Blood, 2010; 116: 4588‑4590
  Google Scholar
• 18. Magnac C., Porcher R., Davi F., Nataf J., Payelle‑Brogard B., TangR.P., Oppezzo P., Lévy V., Dighiero G., Ajchenbaum‑Cymbalista F.: Pre‑dictive value of serum thymidine kinase level for Ig‑V mutationalstatus in B‑CLL. Leukemia, 2003; 17: 133‑137
  Google Scholar
• 19. Matthews C., Catherwood M.A., Morris T.C., Kettle P.J., DrakeM.B., Gilmore W.S., Alexander H.D.: Serum TK levels in CLL identifyBinet stage A patients within biologically defined prognostic sub‑groups most likely to undergo disease progression. Eur. J. Haema‑tol., 2006; 77: 309‑317
  Google Scholar
• 20. Nisman B., Allweis T., Kadouri L., Mali B., Hamburger T., BarasM., Gronowitz S., Peretz T.: Comparison of diagnostic and prog‑nostic performance of two assays measuring thymidine kinase 1activity in serum of breast cancer patients. Clin. Chem. Lab. Med.,2013; 51: 439‑447
  Google Scholar
• 21. Pflug N., Bahlo J., Shanafelt T.D., Eichhorst B.F., Bergmann M.A.,Elter T., Bauer K., Malchau G., Rabe K.G., Stilgenbauer S., Döhner H.,Jäger U., Eckart M.J., Hopfinger G., Busch R., Fink A.M., WendtnerC.M., Fischer K., Kay N.E., Hallek M.: Development of a comprehen‑sive prognostic index for patients with chronic lymphocytic leuke‑mia. Blood, 2014; 124: 49‑62
  Google Scholar
• 22. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N.,Pasternack B.S.: Clinical staging of chronic lymphocytic leukemia.Blood, 1975; 46: 219‑234
  Google Scholar
• 23. Robak T., Hus I., Błoński J., Giannopoulos K., Jamroziak K., RolińskiJ., Smolewski P., Wołowiec D.: Rekomendacje diagnostyczne i terapeu‑tyczne dla przewlekłej białaczki limfocytowej w 2014 r. – raport GrupyRoboczej PTHiT oraz PALG – CLL. Acta Haematol. Pol., 2014; 45: 221‑239
  Google Scholar
• 24. Robak T., Jamroziak K., Robak P.: Current and emerging treat‑ments for chronic lymphocytic leukaemia. Drugs, 2009; 69: 2415‑2449
  Google Scholar
• 25. Sagatys E.M., Zhang L.: Clinical and laboratory prognostic indica‑tors in chronic lymphocytic leukemia. Cancer Control, 2012; 19: 18‑25
  Google Scholar
• 26. SEER. Chronic Lymphocytic Leukemia. Stat Fact Sheets. http://seer.cancer.gov/statfacts/html/clyl.html (02.07.2011)
  Google Scholar
• 27. Stelmach P., Błoński J.Z., Robak T.: Czynniki prognostyczne w prze‑wlekłej białaczce limfocytowej. Onkol. Prakt. Klin., 2014; 10: 322‑329
  Google Scholar
• 28. Stelmach P., Robak T.: Pathogenesis, prophylaxis and treatmentof infections in patients with chronic lymphocytic leukemia. PostępyHig. Med. Dośw., 2013; 67: 560‑568
  Google Scholar
• 29. Suki S., Swan F. Jr., Tucker S., Fritsche H.A., Redman J.R.,Rodriguez M.A., McLaughlin P., Romaguera J., Hagemeister F.B.,Velasquez W.S., Sarris A.H., Younes A., Cabanillas F.: Risk classi‑fication for large cell lymphoma using lactate dehydrogenase,beta‑2 microglobulin, and thymidine kinase. Leuk. Lymphoma,1995; 18: 87‑92
  Google Scholar
• 30. Szánthó E., Bhattoa H.P., Csobán M., Antal‑Szalmás P., ÚjfalusiA., Kappelmayer J., Hevessy Z.: Serum thymidine kinase activity:analytical performance, age‑related reference ranges and valida‑tion in chronic lymphocytic leukemia. PLoS One, 2014; 9: e91647
  Google Scholar
• 31. Xu W., Cao X., Miao K.R., Qiao C., Wu Y.J., Liu Q., Fan L., LiJ.Y.: Serum thymidine kinase 1 concentration in Chinese patientswith chronic lymphocytic leukemia and its correlation with otherprognostic factors. Int. J. Hematol., 2009; 90: 205‑211
  Google Scholar

Pełna treść artykułu